03 Jun 2016
R&D collaboration with Green Cross LabCell
The collaboration with Green Cross LabCell has the potential to enhance Oxford BioMedica’s development pipeline and introduce gene-modified NK cell therapeutics. The collaboration is at an early stage and we look forward to development updates in due course. We remain concerned about the group’s cash position as it only has sufficient cash resources into Q3 2016. We remain at Sell with a 5.3p Target Price.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
R&D collaboration with Green Cross LabCell
Oxford BioMedica plc (OXB:LON) | 201 7.7 1.9% | Mkt Cap: 201.3m
- Published:
03 Jun 2016 -
Author:
Sheena Berry -
Pages:
3
The collaboration with Green Cross LabCell has the potential to enhance Oxford BioMedica’s development pipeline and introduce gene-modified NK cell therapeutics. The collaboration is at an early stage and we look forward to development updates in due course. We remain concerned about the group’s cash position as it only has sufficient cash resources into Q3 2016. We remain at Sell with a 5.3p Target Price.